C. Brunetti

Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.

M. Valerio, N. Gebbia, G. Colucci, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Topotecan in the treatment of brain metastases. A phase II study of GOIM (Gruppo Oncologico dell'Italia Meridionale).

D. Galetta, G. Colucci, V. Lorusso, 2006, Anticancer research.

Phase I /II S tudy o f G emcitabine P lus V inorelbine a s F irst- Line C hemotherapy o f N on-Small-Cell L ung C ancer

S. Palazzo, F. Carpagnano, V. Lorusso, 2000 .

Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer.

S. Palazzo, F. Carpagnano, V. Lorusso, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA).

R. Labianca, A. Rossi, S. Novello, 2011, Lung cancer.

A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study

A. Russo, G. Comella, N. Panza, 2001, British Journal of Cancer.

Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE.

V. Lorusso, A. Rinaldi, L. Biganzoli, 2019, The oncologist.

Weekly Dose-Dense Cisplatin-Epirubicin-Paclitaxel Administration with Granulocyte Colony-Stimulating Factor Support Does Not Substantially Improve Prognosis in Extensive Disease Small-Cell Lung Cancer

A. Russo, G. Comella, I. Carreca, 2005, Oncology.

F1 PERIOPERATIVE ANEMIA AND BLOOD TRANSFUSIONS AS PROGNOSTIC FACTORS IN PATIENTS UNDERGOING RESECTION FOR NON-SMALL CELL LUNG CANCERS

D. Galetta, V. Catalano, M., 2005 .

Weekly cisplatin-paclitaxel-topotecan (CPT) as front-line therapy for extensive disease small cell lung cancer (ED-SCLC). A Southern Italy Cooperative Oncology Group (SICOG) phase II study

A. Russo, G. Comella, N. Panza, 2000 .